Pharmacological blockade of the CD 39/ CD 73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft‐ versus ‐host disease-Reference-Cited by-同舟云学术

Pharmacological blockade of the CD 39/ CD 73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft‐ versus ‐host disease

Published:2019-04-29 Issue:6 Volume:97 Page:597-610
ISSN:0818-9641
Container-title:Immunology & Cell Biology
language:en
Short-container-title:Immunol Cell Biol

Author:

Geraghty Nicholas J¹²³^ORCID,Watson Debbie¹²³^ORCID,Sluyter Ronald¹²³^ORCID

Affiliation:

1. School of Chemistry and Molecular Bioscience University of Wollongong Wollongong NSW 2252 Australia

2. Molecular Horizons University of Wollongong Wollongong NSW 2252 Australia

3. Illawarra Health and Medical Research Institute Wollongong NSW 2252 Australia

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imcb.12251

Reference46 articles.

1. Risk factors for acute GVHD and survival after hematopoietic cell transplantation

2. Graft-versus-host disease

3. INTERLEUKIN-10 DOSE-DEPENDENT REGULATION OF CD4+ AND CD8+ T CELL-MEDIATED GRAFT-VERSUS-HOST DISEASE1

4. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation

5. Purine and pyrimidine receptors

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of cardiac allograft immune responses by microRNA-155;Transplant Immunology;2024-12

2. Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice;Clinical & Translational Immunology;2024-01

3. Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma;International Journal of Molecular Sciences;2023-08-08

4. Review immune response of targeting CD39 in cancer;Biomarker Research;2023-06-07

5. Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft‐versus‐host disease development in humanized mice treated with post‐transplant cyclophosphamide;Immunology & Cell Biology;2023-05-16